Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 201 to 225 of 332

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance and quality standards awaiting development
Title	Type
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]	Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]	Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]	Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]	Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]	Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]	Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]	Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]	Technology appraisal guidance
Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]	Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]	Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]	Technology appraisal guidance
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance
Povorcitinib for treating non-segmental vitiligo [GID-TA12019]	Technology appraisal guidance
Povorcitinib for treating prurigo nodularis [GID-TA12018]	Technology appraisal guidance
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]	Technology appraisal guidance
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]	Technology appraisal guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]	Technology appraisal guidance
Ravulizumab for treating primary IgA nephropathy [ID6703]	Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance

Results per page

10
25
50
All